- Description:Rapid Immunoassay
- Cat. No.:76474-110
- Run time:15 min
Status™ COVID-19/Flu test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV2, influenza A and influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
- Regulatory Status: FDA EUA Authorized for use in a POC setting
- Determinations: nucleocapsid Antigen from SARS-CoV2, Influenza A and Influenza B
- Storage requirements: 35 to 86° F
- Test Time: 15 Minutes
- Flocked nasopharyngeal swab for superior specimen collection and patient comfort
- Made in the USA
A Rapid Immunoassay for the Simultaneous direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from nasopharyngeal swab specimens.
1 test + 1 specimen = 3 results.
CPT CODES: COVID-19: 87811QW, FLU A: 87804QW, FLU B: 87804QW-59.
Sensitivity and Specificity; Flu A (PPA 89.2%,NPA 99.4%); Flu B (PPA86.4%, NPA 99%); COVID-19 (PPA 94%, NPA 100%).
recombinant nucleocapsid protein). Negative Control Swab (1): Inactivated Group B Streptococcus antigen (non-infective). Package Insert /Instructions for use (1). Quick Reference Instruction (1).